placebo effect

Relmada REL-1017 open-label trial, REL-1017 depression treatment, Relmada phase 3 failures, REL-1017 long-term efficacy and safety, REL-1017 Montgomery–Åsberg Depression Rating Scale, Relmada stock price RLMD, REL-1017 placebo response,

Relmada reports positive results from open-label trial of REL-1017 for major depressive disorder

Anika Sharma

Relmada Therapeutics, a central-nervous-system-focused biotech company, has finally glimpsed a ray of optimism after facing setbacks in two phase 3 ...